



Images in medicine

Rubeosis iridis

CrossMark

Dionysios Pagoulatos^{1,8}, Constantine Georgakopoulos¹

¹Department of Ophthalmology, Hippokration Hospital, Athens, Greece, ²Department of Ophthalmology, Medical School, University of Patras, Patras, Greece

&Corresponding author: Dionysios Pagoulatos, Department of Ophthalmology, Hippokration Hospital, Athens, Greece

Key words: Neovascularization, diabetic retinopathy, neovascular glaucoma

Received: 27/08/2017 - Accepted: 06/10/2017 - Published: 29/11/2017

Pan African Medical Journal. 2017;28:279. doi:10.11604/pamj.2017.28.279.13717

This article is available online at: http://www.panafrican-med-journal.com/content/article/28/279/full/

© Dionysios Pagoulatos et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Image in medicine

A 49 year-old man with medical history of diabetes type 2, who presented to the ophthalmology clinic for decreased vision. His most recent hemoglobin A1c was 11.4%. His intraocular pressures were 19 mmHg OD and 35 mmHg OS. Posterior segment exam showed severe proliferative diabetic retinopathy in both Neovascularization of the iris (NVI), also known as rubeosis iridis, is when, blood vessels develop on the anterior surface of the iris in response to retinal ischemia. This condition is often associated with diabetes in advanced proliferative diabetic retinopathy, central retinal vein occlusion, ocular ischemic syndrome and chronic retinal detachment. These new blood vessels may cover the trabecular meshwork and give rise to neovascular glaucoma. Patients with NVI are prone to spontaneous hyphemas as these blood vessels are fragile. Patients with proliferative diabetic retinopathy who develop NVI are treated with panretinal photocoagulation with or without an intravitreal injection of an anti-VEGF medication and with glaucoma treatment.




Figure 1: Rubeosis iridis

